Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell Medical College, New York, NY.
J Natl Cancer Inst. 2020 May 1;112(5):525-532. doi: 10.1093/jnci/djz152.
Childhood cancer survivors exposed to abdominal radiation (abdRT) are at increased risk for diabetes mellitus, but the association between risk and radiation dose and volume is unclear.
Participants included 20 762 5-year survivors of childhood cancer (4568 exposed to abdRT) and 4853 siblings. For abdRT, we estimated maximum dose to abdomen; mean doses for whole pancreas, pancreatic head, body, tail; and percent pancreas volume receiving no less than 10, 20, and 30 Gy. Relative risks (RRs) were estimated with a Poisson model using generalized estimating equations, adjusted for attained age. All statistical tests were two-sided.
Survivors exposed to abdRT (median age = 31.6 years, range = 10.2-58.3 years) were 2.92-fold more likely than siblings (95% confidence interval [CI] = 2.02 to 4.23) and 1.60-times more likely than survivors not exposed to abdRT (95%CI = 1.24 to 2.05) to develop diabetes. Among survivors treated with abdRT, greater attained age (RRper 10 years = 2.11, 95% CI = 1.70 to 2.62), higher body mass index (RRBMI 30+ = 5.00, 95% CI = 3.19 to 7.83 with referenceBMI 18.5-24.9), and increasing pancreatic tail dose were associated with increased diabetes risk in a multivariable model; an interaction was identified between younger age at cancer diagnosis and pancreatic tail dose with much higher diabetes risk associated with increasing pancreatic tail dose among those diagnosed at the youngest ages (P < .001). Radiation dose and volume to other regions of the pancreas were not statistically significantly associated with risk.
Among survivors treated with abdRT, diabetes risk was associated with higher pancreatic tail dose, especially at younger ages. Targeted interventions are needed to improve cardiometabolic health among those at highest risk.
接受腹部放射治疗(abdRT)的儿童癌症幸存者患糖尿病的风险增加,但风险与辐射剂量和体积之间的关系尚不清楚。
参与者包括 20762 名 5 岁儿童癌症幸存者(4568 名暴露于 abdRT)和 4853 名兄弟姐妹。对于 abdRT,我们估计了腹部的最大剂量;整个胰腺、胰腺头部、体部、尾部的平均剂量;以及胰腺体积接受不低于 10、20 和 30Gy 的百分比。使用泊松模型和广义估计方程,调整达到的年龄后,估计相对风险(RR)。所有统计检验均为双侧。
接受 abdRT 的幸存者(中位年龄 31.6 岁,范围 10.2-58.3 岁)比兄弟姐妹(95%置信区间 [CI] 2.02 至 4.23)更有可能患糖尿病,比未接受 abdRT 的幸存者(95%CI 1.24 至 2.05)更有可能患糖尿病。在接受 abdRT 治疗的幸存者中,较高的达到年龄(RRper 10 岁=2.11,95%CI=1.70 至 2.62)、较高的体重指数(RRBMI 30+ = 5.00,95%CI=3.19 至 7.83,参考 BMI 18.5-24.9)和胰腺尾部剂量增加与多变量模型中糖尿病风险增加相关;在癌症诊断年龄较小的患者中,年龄和胰腺尾部剂量之间存在交互作用,随着胰腺尾部剂量的增加,糖尿病风险显著增加(P<0.001)。胰腺其他部位的辐射剂量和体积与风险无统计学显著相关性。
在接受 abdRT 治疗的幸存者中,糖尿病风险与胰腺尾部剂量较高相关,尤其是在年龄较小的患者中。需要有针对性的干预措施来改善高危人群的心脏代谢健康。